Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. [electronic resource]
Producer: 20110819Description: 89-98 p. digitalISSN:- 1097-685X
- Adult
- Aged
- Aged, 80 and over
- Anti-Inflammatory Agents -- administration & dosage
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Cardiopulmonary Bypass
- Chi-Square Distribution
- Complement C5 -- antagonists & inhibitors
- Coronary Artery Bypass -- adverse effects
- Coronary Artery Disease -- immunology
- Double-Blind Method
- Europe
- Female
- Humans
- Infusions, Intravenous
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Myocardial Infarction -- immunology
- North America
- Proportional Hazards Models
- Risk Assessment
- Risk Factors
- Single-Chain Antibodies -- administration & dosage
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.